Tarsus Pharmaceuticals Inc
NASDAQ:TARS
Tarsus Pharmaceuticals Inc
EPS (Diluted)
Tarsus Pharmaceuticals Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tarsus Pharmaceuticals Inc
NASDAQ:TARS
|
EPS (Diluted)
-$3
|
CAGR 3-Years
-66%
|
CAGR 5-Years
-65%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
EPS (Diluted)
$5
|
CAGR 3-Years
-9%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
EPS (Diluted)
-$4
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
EPS (Diluted)
$1
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
0%
|
|
|
Merck & Co Inc
NYSE:MRK
|
EPS (Diluted)
$6
|
CAGR 3-Years
9%
|
CAGR 5-Years
12%
|
CAGR 10-Years
5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
EPS (Diluted)
$11
|
CAGR 3-Years
24%
|
CAGR 5-Years
6%
|
CAGR 10-Years
18%
|
|
Tarsus Pharmaceuticals Inc
Glance View
Tarsus Pharmaceuticals Inc. emerged as a dynamic player in the biotech landscape, primarily driven by its innovative approach to addressing unmet medical needs in ocular health. The company gained attention for its work on developing therapeutic solutions for conditions with significant market potential but limited existing treatments. With a focused approach on tackling Demodex blepharitis, an inflammation of the eyelids caused by a common parasitic mite, Tarsus developed TP-03, an innovative product spearheading its advancement in ocular therapeutics. This biopharmaceutical firm's strategy revolves around capitalizing on its scientific expertise to create niche products that cater to specific, underserved segments, aiming for leadership in targeted therapeutic areas. Tarsus Pharmaceuticals relies on the successful commercialization of its treatments to generate revenue, which primarily comes from sales and partnerships. By shepherding its products through clinical trials and securing regulatory approvals, Tarsus positions itself competitively in the pharmaceutical market. Its business model is centered on developing specialized treatments that fill gaps overlooked by larger pharmaceutical companies, allowing it to carve out a unique space in the industry. Furthermore, by building strategic alliances and leveraging partnerships, Tarsus enhances its capabilities for broader distribution and market penetration, thus ensuring sustainable growth and fostering innovation in therapeutic solutions.
See Also
What is Tarsus Pharmaceuticals Inc's EPS (Diluted)?
EPS (Diluted)
-3.1
USD
Based on the financial report for Dec 31, 2024, Tarsus Pharmaceuticals Inc's EPS (Diluted) amounts to -3.1 USD.
What is Tarsus Pharmaceuticals Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-65%
Over the last year, the EPS (Diluted) growth was 34%. The average annual EPS (Diluted) growth rates for Tarsus Pharmaceuticals Inc have been -66% over the past three years , -65% over the past five years .
You don't have any saved screeners yet